Lumosa Therapeutics Co., Ltd.
Biotechnology - , Taipei City, Taiwan
Lumosa Therapeutics Co., Ltd. Employees
Lumosa Therapeutics Co., Ltd. Senior Management
Lumosa Therapeutics Co., Ltd. Details
Lumosa Therapeutics, a public traded company in Taipei Exchange (6535.TWO), is dedicated to the development of innovative new drugs for the treatment of neurological and inflammatory diseases of unmet medical needs. The company is actively engaged in scientific in-licensing and new drug development under the "reSEARCH and DEVELOPMENT" model. This model is executed by a highly capable and experienced cross-functional teams of translational research, CMC, preclinical, clinical development, project management, regulatory affairs, intellectual property and business development experts. Current products/pipeline include Naldebain®, a long long-acting analgesic injection, launched in Taiwan in 2017 and Singapore in 2021; LT3001, an NCE for the treatment of acute ischemic stroke currently under phase II clinical trial in the US and Taiwan; LT2003, tumor-targeting enzyme prodrug; and LT5001, a novel topical drug for uremic pruritus currently under phase I trial in Taiwan.
Lumosa Therapeutics Co., Ltd. Technologies
Captcha
reCAPTCHA
Email Providers
Outlook
Marketing Automation
Active Campaign
Load Balancers
Apache
Other
Microsoft Office 365
Hosting
Google Cloud Hosting